94,067 Chemed Corporation $CHE Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Chemed position by 99%, selling 94,067 shares and retaining 933 shares worth approximately $471,000. Institutional investors collectively own 95.85% of the company.
• Chemed reported quarterly EPS of $6.06, exceeding estimates of $5.60, while revenue rose 8.8% year over year to $673.25 million. The company raised its quarterly dividend to $0.70 per share, implying a 0.5% annual yield.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $554.60; price targets range from $590 at Oppenheimer to $650 at UBS. Company insiders sold 9,190 shares worth $4.83 million over the past 90 days.

Curated Wealth Partners LLC lessened its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 99.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 933 shares of the company's stock after selling 94,067 shares during the period. Curated Wealth Partners LLC's holdings in Chemed were worth $471,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Chemed during the second quarter valued at approximately $691,290,000. First Trust Advisors LP raised its position in shares of Chemed by 24.7% during the first quarter. First Trust Advisors LP now owns 236,392 shares of the company's stock worth $89,295,000 after acquiring an additional 46,791 shares during the last quarter. Copeland Capital Management LLC grew its holdings in Chemed by 1.3% during the third quarter. Copeland Capital Management LLC now owns 146,833 shares of the company's stock valued at $74,162,000 after purchasing an additional 1,826 shares during the period. Bank of America Corp DE bought a new position in Chemed in the second quarter valued at approximately $48,255,000. Finally, Caisse de depot et placement du Quebec bought a new position in shares of Chemed in the 2nd quarter valued at about $44,309,000. 95.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Chemed

In other Chemed news, Director Patrick P. Grace sold 190 shares of Chemed stock in a transaction on Friday, July 31st. The shares were sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the transaction, the director directly owned 3,533 shares of the company's stock, valued at $1,879,556. This trade represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Spencer S. Lee sold 1,000 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the sale, the executive vice president owned 13,912 shares in the company, valued at approximately $7,526,948.48. The trade was a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,190 shares of company stock valued at $4,833,160 over the last ninety days. 3.33% of the stock is currently owned by company insiders.

Chemed Stock Down 0.6%

CHE stock opened at $512.20 on Friday. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $557.00. The company has a market capitalization of $6.69 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 2.07 and a beta of 0.51. The business's 50 day moving average price is $517.57 and its two-hundred day moving average price is $471.11. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, topping the consensus estimate of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. During the same quarter in the previous year, the firm posted $4.27 earnings per share. Chemed's quarterly revenue was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, analysts forecast that Chemed Corporation will post 23.55 earnings per share for the current fiscal year.

Chemed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, August 17th. This is an increase from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is presently 14.06%.

Analysts Set New Price Targets

Several research firms have recently commented on CHE. Wall Street Zen raised Chemed from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 10th. Oppenheimer raised their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Weiss Ratings upgraded shares of Chemed from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. UBS Group started coverage on Chemed in a report on Friday, September 25th. They issued a "buy" rating and a $650.00 price objective for the company. Finally, Bank of America reaffirmed a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $554.60.

Chemed Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.